iBio to Participate in the H.C. Wainwright Global Investment Conference
May 18 2022 - 8:00AM
iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a developer of
next-generation biopharmaceuticals and pioneer of the sustainable,
plant-based
FastPharming® Manufacturing System,
today announced that it will participate virtually in the H.C.
Wainwright Global Investment Conference. The hybrid conference will
take place May 23-26, 2022.
iBio's pre-recorded presentation will be
available on demand during the event for all registered attendees.
Beginning on Tuesday, May 24, 2022, the presentation will also be
available on the Company's website at www.ibioinc.com under "News
& Events" in the Investors section.
About iBio, Inc.
iBio is a developer of next-generation
biopharmaceuticals and a pioneer in sustainable, plant-based
biologics manufacturing. Its FastPharming® System
combines vertical farming, automated hydroponics, and novel
glycosylation technologies to rapidly deliver high-quality
monoclonal antibodies, vaccines, bioinks and other proteins. iBio
is developing proprietary biopharmaceuticals for the treatment of
cancers, as well as fibrotic and infectious diseases. The Company’s
wholly-owned subsidiary, iBio CDMO LLC, provides
FastPharming Contract Development and
Manufacturing Services along with GlycaneeringSM
Development Services for advanced recombinant protein design. For
more information, visit www.ibioinc.com.
Contact:
Stephen KilmeriBio, Inc.Investor Relations(646)
274-3580skilmer@ibioinc.com
iBio (AMEX:IBIO)
Historical Stock Chart
From Aug 2024 to Sep 2024
iBio (AMEX:IBIO)
Historical Stock Chart
From Sep 2023 to Sep 2024